Trials / Unknown
UnknownNCT05510466
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
Analysis of Efficiency and Tolerance of Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis Occuring During First-line BRAFinh/MEKinh Therapy.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 18 (estimated)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1 agent to TT may be proposed as a second line strategy. This observational survey aims at investigating the benefit/risk ratio of this triple combination in a small cohort of patients.
Conditions
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2023-02-20
- Completion
- 2023-03-01
- First posted
- 2022-08-22
- Last updated
- 2022-08-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05510466. Inclusion in this directory is not an endorsement.